Big Pharma's R&D Booster Shot

In their quest to develop new drugs, Western pharmaceutical companies are increasingly teaming up with companies in China and India
Manpreet Romana/AFP/Getty Images

In the late 1990s, scores of U.S. multinationals were catching on to the cost-cutting benefits of sending work to Asia. Not Big Pharma. The industry was bulging with profits and confidence. Whatever money could be saved by shifting drug development work to India or China would have seemed inconsequential compared with the billions of dollars at stake in a potential new blockbuster.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.